Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Post-treatment Normallized Urodynamic Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Correlations With Voiding Diary, King's Health Questionnaire, and Overactive Bladder Sympto

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01627145

Enrollment

300

Registered

2012-06-25

Start date

2012-08-31

Completion date

2015-07-31

Last updated

2012-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder Syndrome

Keywords

overactive bladder syndrome, derusor overactivity, urodynamic studies, bladder oversensitivity

Brief summary

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Conelations With Voiding Diary, King's Health Quentionaire, Overactive Bladder Sympton Scores and Patient Perception of Bladder Condition.

Interventions

DRUGSolifenacin

Solifenacin 5 mg qd,

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* female patients within 18 years old to 99 years old with overactive bladder syndrome

Exclusion criteria

* unwilling or unable to perform testing procedure

Design outcomes

Primary

Measure	Time frame
The percentage of normalized urodynamic pattern after treatment	12 weeks

Secondary

Measure	Time frame
The percentage of recurrence rates after treatment during follow-up and further to analyze the risk factors of recurrence	48 months

Countries

Taiwan

Contacts

Primary ContactHo-Hsiung Lin, PhD

hhlin@ntuh.gov.tw+886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026